This document lists 50 publications by Dr. Gilbert Lefèvre from 1987 to 2008. The publications cover a range of topics including: - Anti-Müllerian hormone and related monoclonal antibodies (publications 1-3) - Pharmacokinetic studies of drugs like hirudin, artemether, and rivastigmine (publications 4-10, 23-25, 45-50) - Drug interaction and safety studies of antimalarial and Alzheimer's drugs (publications 26-28, 30-33, 36, 38, 40, 41, 44) - Pharmacokinetic studies of antimalarial drugs in specific populations like children and Africans (publications 29, 42, 43)

1. September 2015
DR. GILBERT LEFEVRE - PUBLICATIONS
1. Josso N, Vigier B, Picard JY, Lefèvre G, Tran D. Anti-Müllerian Hormone. The fifth International Meeting of
the International Society of Differentiation, Boulder, Collorado, USA, 3-7 August 1987.
2. Legeai L, Lefèvre G, Vigier B, Picard JY, Josso N. A monoclonal antibody against human testicular Anti-
Müllerian Hormone. Am J Reprod Immunol Microbiol 1988, 18: 39-42.
3. Lefèvre G, Tran D, Hœbeke J, Josso N. Anti-idiotype antibodies to a monoclonal antibody raised against Anti-
Müllerian Hormone exhibit anti-Müllerian biological activity. Mol Cell Endocrinol 1989, 62: 125-133.
4. Cardot JM, Lefèvre G, Godbillon J. Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous
administration. J Pharm Biopharm 1994, 22: 147-156.
5. Zoldhelyi P, Janssens S, Lefèvre G, Van de Werf F. Were plasma hirudin levels in the GUSTO-2A trial higher
than expected from pharmacokinetics studies in volunteers with stable coronary disease ? American College of
Cardiology, 44th
Annual Scientific Session, April 1995.
6. Zoldhelyi P, Janssens S, Lefèvre G, Collen D, Van de Werf F. Effects of heparin and hirudin (CGP 39393) on
thrombin generation during thrombolysis for acute myocardial infarction. Circulation 1995, Vol 92 (Suppl I),
No 8.
7. Zoldhelyi P, Janssens S, Lefèvre G, Collen D, Van de Werf F. Accelerated thrombin generation during
conjunctive treatment of myocardial infarction with t-PA and r-hirudin. XVth
Congress of the International
Society on Thrombosis and Haemostasis. Jerusalem, Israel, June 11-16, 1995.
8. Zoldhelyi P, Janssens S, Lefèvre G, Van de Werf F. Plasma hirudin and aPTT levels in acute patients of the
GUSTO-2A trial compared with hirudin levels and aPTT in volunteers with stable coronary disease. Eur Heart
J 1995, 16 (Suppl): 177.
9. Kinoshita T, Kawasugi K, Yamanaka H, Sagawa T, Koyama Y, Hama H, Hamauzu T, Ogushi J, Nishimura M,
Kuyama Y, Matsuda J, Kamakura M, Miyake K, Nagase M, Yasuda K, Kazama M, Yamanaka M, Lefèvre G.
Clinical evaluation of recombinant hirudin, CGP 39 393. Phase I study: single and multiple dose administration
in healthy volunteers. J Clinical Therapeutic and Medicines [Article in Japanese] 1995, 6: 1143-1175.
10. Gygax D, Botta L, Ehrat M, Graf P, Lefèvre G, Oroszlan P, Pfister C. Immuno and other approaches in
pharmacokinetics. 11th
Bioanalytical Forum, University of Surrey, Guildford, UK and 4th
International
Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Vienna, Austria, 1995. In Methodological
Surveys in Bioanalysis of Drugs, Vol 24. Biofluid assay for peptide-related and other drugs; Ed. E. Reid, H. M.
Hill; I. D. Wilson, 1996, pp 11-19.
11. Lefèvre G, Duval M, Botta L, Godbillon J. Direct microtitre plate radioimmunoassay of savoxepine in
unextracted plasma. J Immunoassay 1996, 17(1): 29-46.
12. Gygax D, Botta L, Ehrat M, Graf P, Lefèvre G, Oroszlan P, Pfister C. Immunoassays in monitoring
biotechnological drugs. Ther Drug Monit 1996, 18 (4): 405-409.
13. Godbillon J, Cardot JM, Lecaillon JB, Lefèvre G, Sioufi A. Bioequivalence assessment: a pharmaceutical
industry perspective. Eur J Drug Metab Pharmacokinet 1996, 21(2): 153-158.
14. Müller P, Botta L, Lefèvre G, Ezzet F. Pharmacokinetics of a new oestradiol matrix patch in healthy
postmenopausal volunteers and symptomatic women. World Congress of Gynecology, November 1996,
Sydney, Australia.
15. Lefèvre G, Duval M, Gauron S, Piraino A, Morgan J, Palmisano M, Brookman L, Rolan P, Godbillon J, Close
P. The effects of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin (™REVASC).
Sixth European Congress of Biopharmaceutics and Pharmacokinetics, Athens, Greece, April 22-24th
, 1996. Eur
J Drug Metab Pharmacokinet 1996, (Suppl) No 263: 89.
16. Amin DM, Mant TGK, Walker SM, Kerry R, Lloyd P, Lefèvre G, Close P. Effect of a 15-minute infusion of
DDAVP on the pharmacokinetics and pharmacodynamics of ™REVASC during a four-hour intravenous
infusion in healthy male volunteers. Thromb Haemostas 1997, 77: 127-132.
17. Colussi D, Parisot C, Brunner L, Rossolino M, Lefèvre G. Protein binding in plasma of valsartan, a new
angiotensin II receptor antagonist. J Clin Pharmacol 1997, 37(3): 214-221.

2. September 2015
18. Lefèvre G, Duval M, Gauron S, Brookman L, Rolan P, Morris T, Piraino A, Morgan J, Palmisano M, Close P.
The effects of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin Pharmacol
Ther 1997, 62: 50-59.
19. Colussi D, Parisot C, Lefèvre G. Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme
inhibitor. J Clin Pharmacol 1998, 38: 727-735.
20. Thomsen M, Lefèvre G, Ezzet F, Bindschedler M. Co-artemether: pharmacokinetic profile of a combined anti-
malaria compound treatment. 2nd
European Congress on Tropical Medicine, Liverpool, UK, 14-18th
September
1998, Abstr. No. P31.
21. Colussi D, Parisot C, Lefèvre G. Binding of iralukast to serum proteins and erythrocytes: measurements using
ultrafiltration and an erythrocyte partitioning method. Eur J Pharm Sci 1998, 7: 167-173.
22. Parisot C, Colussi D, Lefèvre G. Co-artemether: protein binding of artemether and lumefantrine. 7th
European
Congress of Biopharmaceutics and Pharmacokinetics (ECBP) and 5th
Congress of the European Federation of
Pharmaceutical Sciences (EUFEPS), Jerusalem, Israel, 25-30 April 1999. Eur J Pharm Sci 1999, 8(2): xxvii,
Abstr. No. 110.
23. Colussi D, Parisot C, Legay F, Lefèvre G. Binding of artemether and lumefantrine to plasma proteins and
erythrocytes. Eur J Pharm Sci 1999, 9: 9-16.
24. Lefèvre G, Thomsen M. Clinical pharmacokinetics of artemether and lumefantrine (Riamet
). Clin Drug Invest
1999, 18(6): 467-480.
25. Lefèvre G, Gauron S. Automated quantitative determination of the new renin inhibitor CGP 60536 by high-
performance liquid chromatography. J Chromatogr 2000, 738(1): 129-136.
26. Lefèvre G, Bindschedler M, Ezzet F, Schaeffer N, Meyer I, Thomsen M. Pharmacokinetic interaction trial
between co-artemether and mefloquine. Eur J Pharm Sci 2000, 10(2): 141-151.
27. Lefèvre G, Duval M, Poncin A. Direct micro-radioimmunoassay of the new renin inhibitor CGP60536. J
Immunoassay 2000, 21(1): 65-84.
28. Bindschedler M, Lefèvre G, Ezzet F, Schaeffer N, Meyer I, Thomsen M. Cardiac effects of co-artemether
(artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur J Clin
Pharmacol 2000, 56: 375-381.
29. Lefèvre G, Looareesuwan S, Treeprasertsuk S, Krodsood S, Silachamroon U, Gathmann I, Mull R, Bakshi R.
A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug resistant
Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001, 64(5,6): 247-256.
30. Bindschedler M, Lefèvre G, Degen P, Sioufi A. Comparison of the cardiac effects of the antimalarials co-
artemether and halofantrine in healthy participants. Am J Trop Med Hyg 2002, 66(3): 295-300.
31. Lefèvre G. No evidence of cardiotoxicity of co-artemether in comparison to halofantrine (oral communication).
The Royal College of Physicians of London, 11 St
Andrew Place, Regent Park, London, UK. 25-April-2002.
32. Lefèvre G, Carpenter P, Souppart C, Schmidli H, Martin JM, Lane A, Ward C, Amakye D. Interaction trial
between artemether-lumefantrine (Riamet®
) and quinine in healthy subjects. J Clin Pharmacol 2002, 42(10):
1147-1158.
33. Lefèvre G, Carpenter P, Souppart C, Schmidli H, McClean M, Stypinski D. Pharmacokinetics and
electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet®
) with concomitant
administration of ketoconazole in healthy subjects. Br J Clin Pharmacol 2002, 54: 485-492.
34. Lefèvre G. Antipaludiques et Cardiotoxicité – Profil de tolérance de Coartem®
et interactions médicamenteuses
(communication orale). Universités Africaines Coeur-Paludisme, 16-17th
Novembre 2002, Paris, France.
35. Lefèvre G. Pharmacokinetic and cardiosafety data on an artemisinin combination (oral communication). 8th
Conference of the International Society of Travel Medicine (CISTM8), 9th
May 2003, New York, USA.
36. Lefèvre G et al. 8th
Conference of the International Society of Travel Medicine (CISTM8), 7-11th
May 2003,
New York, USA.
Presentation of 6 posters on Coartem®
/Riamet®
:
36. Pharmacokinetics of artemether-lumefantrine (Coartem®
/Riamet®
), including the effect of food (Lefèvre et al.)
37. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand
(Lefèvre et al.)
38. Interaction trial between artemether-lumefantrine (Riamet®
) and quinine in healthy subjects (Lefèvre et al.)

3. September 2015
39. Pharmacokinetic interaction trial and study on cardiac effects between co-artemether and Mefloquine (Lefèvre et al.)
40. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet®
) with concomitant administration of
ketoconazole in healthy subjects (Lefèvre et al.)
41. Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants (Bindschedler et al.)
42. Lefèvre G, Makanga M, Falade C, Ibarra de Palacios P, Denouël J, Schmidli H. Pharmacokinetics of the 6-dose
regimen of co-artemether in African infants and children with acute, uncomplicated falciparum malaria. 52nd
Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), 3-7 December 2003,
Philadelphia, PA, USA.
43. Makanga M, Fallade C, Premji Z, Ibarra de Palacios P, Stockmeyer M, Lefèvre G. Efficacy, safety and
pharmacokinetics of a co-artemether (artemether 20 mg, lumefantrine 120 mg) 6-dose regimen in african
infants and children with acute, uncomplicated Plasmodium falciparum malaria (oral communication). Africa
European Conference on Travel Medicine (AECTM), 8-11th
February 2004, Cape Town, South Africa.
44. Lefèvre G. Clinical pharmacokinetics and cardiosafety (QTc) profile of Coartem®
. Advisory Board Meeting.
10-11 March 2005, Dakar, Senegal.
45. Lefèvre G, Sędek S, Huang A, Saltzman M, Rosenberg M, Kiese B, Fordham P. Pharmacokinetics of a
transdermal patch formulation of rivastigmine in healthy volunteers: relative effects of body site application. J
Clin Pharmacol 2007, 47: 471-478.
46. Cummings J, Lefèvre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch.
Neurology 2007, 69: S10-S13.
47. Abdulla S, Sagara I, Borrmann S, Nahum A, Bassat Q, Hamel M, Ogutu B, Björkman A, Andriano K, Cousin
M, Lefèvre G, Ubben D. Efficacy and safety of a new dispersible tablet formulation of artemether-lumefantrine
in pediatric patients with acute uncomplicated Plasmodium falciparum malaria – Randomized, investigator-
blinded, multicenter comparison with the crushed tablet. 56nd
Annual Meeting of the American Society of
Tropical Medicine and Hygiene (ASTMH), 4-8th
November 2007, Philadelphia, PA, USA.
48. Mercier F, Lefèvre G, Huang A, Schmidli H, Amzal B, Appel-Dingemanse S. Rivastigmine exposure provided
by a transdermal patch versus capsules. Curr Med Res Opin 2007, 23: 3199-3204.
49. Mercier F, Lefèvre G, Huang A, Schmidli H, Amzal B, Appel-Dingemanse S. Rivastigmine exposure provided
by a transdermal patch versus capsules (poster). 10th
International Hong Kong / Springfield Pan-Asian
Symposium on Advances in Alzheimer Therapy, 28 February-1 March 2008, Hong Kong.
50. Lefèvre G, Sędek G, Jhee S, Leibowitz MT, Huang A, Enz A, Maton S, Ereshefsky L, Lopez P, Ho YY, Sagan
C, Appel-Dingemanse S. Pharmacokinetics and bioavailability of the novel daily rivastigmine transdermal
patch compared with twice-daily capsules in patients with mild-to-moderate Alzheimer’s disease. Clin
Pharmacol Ther 2008, 83: 106-114.
51. Lefèvre G, Pommier F, Sędek G, Allison M, Huang A, Kiese B, Ho YY, Appel-Dingemanse S.
Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral
solution in healthy elderly subjects. J Clin Pharmacol 2008, 48: 246-252.
52. Hatz C, Soto J, Nothdurft HD, Zoller T, Weitzel T, Loutan L, Bricaire F, Gay F, Burchard GD, Andriano K,
Lefèvre G, Ibarra de Palacios P, Genton B. Treatment of acute uncomplicated falciparum malaria with
artemether-lumefantrine in non-immune populations: a safety, efficacy and pharmacokinetic study. Am J Trop
Med Hyg 2008, 78(2): 241-247.
53. Shua-Haim J, Smith S, Picard F, Sedek S, Athalye S, Pommier F, Lefèvre G. Steady-state pharmacokinetics of
rivastigmine in patients with mild to moderate Alzheimer’s disease not affected by co-administration of
memantine. Clin Drug Invest 2008, 28(6): 361-374.
54. Borrmann S, Sallas W, Marrast AC, Lefèvre G, Kern S. Impact of African diet components on exposure to
lumefantrine in infants and children receiving artemether-lumefantrine (Coartem) for uncomplicated malaria.
ICTM 2008, XVIIth
International Congress for Tropical Medicine and Malaria, Sept 29-Oct 3, 2008, Jeju
Island, Korea.
55. Borrmann S, Djimé A, Abdulla S, Lefèvre G, Andriano K. Pharmacokinetic-pharmacodynamic features of
artemether-lumefantrine administered as dispersible tablet compared to the crushed commercial tablet in
African children with P. falciparum malaria. ICTM 2008, XVIIth
International Congress for Tropical Medicine
and Malaria, Sept 29-Oct 3, 2008, Jeju Island, Korea.

4. September 2015
56. Lefèvre G, Abdulla S, Lyimo J, Agyemang A, Reynolds C, Pascoe S, Fitoussi S, Yeh CM, Nuortti M, Rivière
GJ, Séchaud R. Early development of the new artemether-lumefantrine dispersible tablet: Palatability and
pharmacokinetics in healthy subjects. ASTMH 2008, 57th
Annual Meeting of the American Society of Tropical
Medicine and Hygiene, 7/11-Dec-2008, New Orleans, LA, USA.
57. Borrmann S, Sallas W, Marrast AC, Lefèvre G, Kern S. Exposure to lumefantrine in infants receiving
artemether-lumefantrine (Coartem) for uncomplicated malaria: impact of African diet components. ASTMH
2008, 57th
Annual Meeting of the American Society of Tropical Medicine and Hygiene, 7-11-Dec-2008, New
Orleans, LA, USA.
58. Djimdé A, Borrmann S, Abdulla S, Lefèvre G, Andriano K. Pharmacokinetic and pharmacodynamic
characteristics of a new dispersible tablet formulation of artemether-lumefantrine compared to the crushed
commercial tablet in African children with P. falciparum malaria. ASTMH 2008, 57th
Annual Meeting of the
American Society of Tropical Medicine and Hygiene, 7/11-Dec-2008, New Orleans, LA, USA.
59. Abdulla S, Sagara I, Borrmann S, D’Alessandro U, Gonzales R, Hamel M, Ogutu B, Martensson A, Lyimo J,
Maiga H, Sasi P, Nahum A, Bassat Q, Juma E, Otieno L, Björkman A, Beck HP, Andriano K, Cousin M,
Lefèvre G, Ubben D, Premji Z. Efficacy and safety of artemether-lumefantrine dispersible tablet in African
infants and children with uncomplicated malaria: a randomized, investigator-blinded, multicentre comparison
with the crushed commercial tablet. Lancet 2008, 372: 1819-1827.
60. Lefèvre G, Büche M, Sędek G, Maton S, Enz A, Lorch U, Sagan C, Appel-Dingemanse S. Similar rivastigmine
pharmacokinetics and pharmacodynamics in Japanese and White healthy participants following the application
of novel rivastigmine patch. J Clin Pharmacol 2009, 49: 430-443.
61. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of
Alzheimer’s disease: a review. Int J Clin Pract 2009, 63(5): 799-805.
62. Djimdé A and Lefèvre G. Understanding the pharmacokinetics of Coartem®
. Malar J 2009, 8 (Suppl 1): S4.
63. Juma E, Sallas WM, Lyimo J, Marrast AC, Lefèvre G, Djimdé A. Exposure to lumefantrine in infants and
children receiving artemether-lumefantrine for uncomplicated malaria: impact of African diet components.
PMA and KPA Conferences 2009.
64. Djimdé A, Sallas WM, Lyimo J, Marrast AC, Lefèvre G, Borrmann S. Exposure to lumefantrine in infants and
children receiving artemether-lumefantrine for uncomplicated malaria: impact of African diet components. 5th
Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference, 2-6th
Nov 2009, Nairobi, Kenya.
65. Abdulla S, Lefèvre G, Lyimo J, Agyemang A, Reynolds C, Pascoe S, Fitoussi S, Yeh CM, Nuortti M, Rivière
GJ, Séchaud R. Early development of the new artemether-lumefantrine dispersible tablet: palatability and
pharmacokinetics. 5th
Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference, 2-6th
Nov
2009, Nairobi, Kenya.
66. Borrmann S, Sallas WM, Machevo S, Gonzáles R, Björkman A, Mårtensson A, Hamel M, Juma E, Ogutu B,
Djimdé A, D’Alessandro U, Marrast AC, Lefèvre G, Kern SE. The effect of food consumption on lumefantrine
bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem®
)
for acute uncomplicated Plasmodium falciparum malaria. Trop Med Int Health 2010, 15(4): 434-441.
67. Borrmann S, Sallas WM, Machevo S, Gonzáles R, Björkman A, Mårtensson A, Hamel M, Juma E, Ogutu B,
Djimdé A, D’Alessandro U, Marrast AC, Lefèvre G, Kern SE. The effect of food consumption on lumefantrine
bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem®
)
for acute uncomplicated Plasmodium falciparum malaria. Trop Med Int Health 2010, 15(4): 434-341.
68. Abdulla S, Amuri B, Kabanywanyi AM, Ubben D, Reynolds C, Pascoe S, Fitoussi S, Yeh CM, Nuortti M,
Séchaud R, Kaiser G, Lefèvre G. Early clinical development of artemether-lumefantrine dispersible tablet:
palatability of three flavours and bioavailability in healthy subjects. Malar J 2010, 9: 253-261.
69. Lefèvre G, Klingelhöfer L, Mollenhauer B, Kassubek J, Ebersbach G, Tenenbaum N. Pharmacokinetics of
rivastigmine patch (Exelon) in patients with Parkinson’s disease dementia. The 10th
International Conference
on Alzheimer’s & Parkinson’s diseases. Barcelona, Spain, March 9-13, 2011.
70. Lefèvre G, Marrast AC, Grüninger H. Novartis malaria initiative: best practice example of pharmaceutical
industry’s engagement in the fight against malaria. Ann NY Acad Sci 2011, 1222: 19-29.
71. Eckermann G, Lefèvre G. Cytochrome P-450 enzymes and their influence on the efficacy and safety of
cholinesterase inhibitor treatment for Alzheimer’s disease. Abstract accepted for the 164th
Annual Meeting of
The American Psychiatric Association (APA), May 14-18, 2011, Honolulu, Hawaii.

5. September 2015
72. Djimdé A, Tekete M, Abdulla S, Lyimo J, Bassat Q, Mandomando I, Lefèvre G, Borrmann S. Pharmacokinetic
and pharmacodynamic characteristics of a new pediatric formulation (dispersible tablet) of artemether-
lumefantrine in African children with uncomplicated malaria. Antimicrob Agents Chemother 2011, 55(9):
3994-3999.
73. Meremikwu M, Alao MJ, Gbadoé AD, Tshefu A, Lefèvre G, Walter V, Cousin M, Hamed K, Ogutu B.
Evaluation of the efficacy, safety and PK of artemether-lumefantrine dispersible tablet in the treatment of acute
uncomplicated Plasmodium falciparum malaria in infants weighing <5 kg. 7th European Congress on Tropical
Medicine & International Health, Oct 3-6, 2011, Barcelona, Spain.
74. Bassat Q, Menéndez C, Machevo S, Nahum A, Lyimo J, Maiga H, Märtensson A, Bashraheil M, Ouma P,
Walter V, Nwaiwu O, Kipkeu C, Lefèvre G, Ogutu B. Artemether-lumefantrine (Coartem) body weight ranges
are associated with similar efficacy and safety in African infants and children with uncomplicated falciparum
malaria. Malar J 2011, 10(1): 369.
75. Carrasquilla G, Barón C, Monsell EM, Cousin M, Walter V, Lefèvre G, Sander O, and Fisher LM.
Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-
lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg
2012, 86(1): 75-83.
76. Hamed K, Meremiku M, Alao MJ, Gbadoé, Tshefu A, Lefèvre G, Walter V, Cousin M, Ogutu B. Evaluation of
the efficacity, safety and pharmacokinetics of artemether-lumefantrine dispersible tablet in the treatment of
acute uncomplicated Plasmodium falciparum malaria in infants weighing <5 kg. Abstract at the VIII
International Congress for Tropical Medicine and Malaria (ICTMM) and XLVIII Congress of the Brazilian
Society for Tropical Medicine. Rio de Janeiro, Brazil, 2012.
77. Jain JP, Lakshminarayana SB, Lefèvre G, Sivasubramanian R, Blasco F, Sunkara G. Differences in the
pharmacokinetics of currently approved antimalarial drugs in uncomplicated malaria patients compared to
healthy subjects. Malar J 2012, 11 S1 P118.
78. Lefèvre G, Bhad P, Jain JP, Stein D, Kalluri S, Hardike D, Kaiser G. The novel 80/480 mg tablet formulation
of artemether-lumefantrine (Coartem®
) is bioequivalent to a dose of four individual standard tablets in healthy
volunteers. Abstract/poster at 61st
Annual Meeting of the American Society of tropical Medicine and Hygiene
(ASTMH), Atlanta, Georgia, USA, 2012.
79. Diagana T, Leong J, Lefèvre G. Discovery and early development of novel antimalarial drugs for the treatment
pf P. falciparum and P. viva malaria. In: Keystone meeting Drug Discovery for Protozoan Parasites (J1), 15-20
January 2012, Santa Fe, USA.
80. Lefèvre G, Bhad P, Jain JP, Kalluri S, Cheng Y, Stein DS. Evaluation of two novel tablet formulations of
artemether-lumefantrine (Coartem®
) for bioequivalence in a randomized, open-label, two-period study. Malar
J 2013, 12: 312-322.
81. Lamorde M, Byakika-Kibwika P, Mayito J, Nabukeera L, Ryan M, Hanpithakpong W, Lefèvre G, Back D,
Khoo S, Merry C. Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-
based tuberculosis treatment. AIDS 2013, 27(6): 961-965.
82. White N, Nosten F, Pukrittayakamee S, Jittmala P, Pyae Phyo A, Rueangweerayut R, Diagana T, Li R,
Magnusson B, Lefèvre G, Jain JP, Leong J. Rapid clearance of parasitemia by the novel spiroindolone
KAE609 in a phase 2 open-label study of adults with acute, uncomplicated Plasmodium falciparum or vivax
malaria mono-infection. 62nd
Annual Meeting of the American Society of Tropical Medicine and Hygiene
(ASTMH), Washington DC, USA, 2013.
83. White N, Pukrittayakamee S, Pyae Phyo A, Rueangweerayut R, Nosten F, Jittmala P, Jain JP, Lefèvre G, Li R,
Magnusson B, Diagana T, Leong FJ. Spiroindolone KAE609 for falciparum and vivax malaria. NEJM 2014,
371(5): 403-410.
84. Leong FJ, Li R, Jain JP, Lefèvre G, Magnusson B, Diagana T, Pertel P. A first-in-human randomized, double-
blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial spiroindolone
KAE609 (Cipargamin) to assess its safety, tolerability and pharmacokinetics in healthy adult volunteers.
Antimicrob Agents Chemother 2014, 58(10): 1-6.
85. Leong FJ, Li R, Jain JP, Lefèvre G, Magnusson B, Diagana T, Pertel P. A first-in-human randomized, double-
blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial spiroindolone
KAE609 (cipargamin), to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers.
Challenges in Malaria Research Conference 2014 (Sept), University of Oxford, UK.

6. September 2015
86. Stein DS, Jain JP, Lickliter J, Kangas M, Machineni S, Griffin P, Lefèvre G. A phase 1 study evaluation of the
pharmacokinetic/pharmacodynamic interaction of the antimalarial agents KAE609 (cipargamin) and
piperaquine. Challenges in Malaria Research Conference 2014 (Sept), University of Oxford, UK.
87. Stein DS, Jain JP, Lickliter J, Kangas M, Machineni S, Griffin P, Lefèvre G. A phase 1 evaluation of the
pharmacokinetic/pharmacodynamic interaction of the antimalarial agents KAE609 and Piperaquine (PPQ). 63rd
Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) 2014 (Nov), New
Orleans, USA.
88. Tiono AB, Tinto H, Alao MJ, Meremikwu M, Tshefu A, Ogutu B, Ouedraogo A, Lingani M, Cousin M,
Lefèvre G, Jain JP, Duparc S, Hamed K. Increased systemic exposures of artemether and dihydroartemisinin in
infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine
(Coartem®
). Malar J 2015, 14: 157-167.
89. Stein D, Jain JP, Kangas M, Lefèvre G, Machineni S, Griffin P, and Lickliter J. Open-Label, single-dose,
parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609
(cipargamin) and piperaquine. Antimicrob Agents Chemother 2015, 59(6): 3493-500.
90. Lefèvre G, Callegari F, Xiong Y, Nox S. Absence of effect of renal impairment on rivastigmine
pharmacokinetics in patients with Alzheimer ’s Disease. 1st
Congress of the European Academy of Neurology.
Berlin, Germany, June 20-23 2015.
91. Lefèvre G, Callegari F, Xiong Y. Absence of effect of renal impairment on rivastigmine pharmacokinetics in
patients with Alzheimer’s Disease. The 2015 Alzheimer’s Disease Congress, London, UK, June 23-25 2015.
92. Jain JP, Ganesan S, Lefèvre G, Sunkara G. Estimation of amount of artemether and lumefantrine excreted
through breast milk. 9th
European Congress on Tropical Medicine and International Health (ECTMIH 2015),
Basle, Switzerland, 6-13 September 2015.
93. Jain JP, Ganesan S, Lefèvre G, Sunkara G. Estimation of amount of artemether and lumefantrine excreted
through breast milk. 64th
Annual Meeting of the American Society of Tropical Medicine and Hygiene
(ASTMH), Philadelphia, PA, USA, 25-29 October 2015.
94. WWARN Lumefantrine PK/PD Study Group. Artemether-lumefantrine treatment of uncomplicated
Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations
and therapeutic response using individual patient data. BMC Mediciene 1015, 13:227-246.
95. Lefèvre G, Callegari F, Gsteiger S, Xiong Y. No effect of renal impairment on rivastigmine pharmacokinetics
in patients with Alzheimer’s Disease. Final version under submission.
96. Han Y, Li L, Lefèvre G, Chen Y, Zeng S, Ufer M, Hockey HU, Zhao R. Pharmacokinetics of the rivastigmine
transdermal patch in healthy Chinese subjects after single and multiple administrations. To be submitted.